Keyword: Department of Health and Human Services (HHS)
The next courtroom showdown in the battle over drug prices in TV ads is set for Jan. 13 with Merck, Eli Lilly, Amgen and ANA versus HHS.
Gilead Sciences balked at licensing the U.S. government's HIV-prevention patent rights, and now the feds are striking back.
Transparency in drug pricing sounds like a great idea, but a new study finds that almost none of the state laws provide real price insights.
The government's patents on Gilead's Truvada have made plenty of headlines lately, and that's a distraction, Gilead figures.
Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.
The Trump administration unveiled a plan to import cheaper drugs from Canada, reversing years of HHS and FDA opposition.
In his push to prove himself as the toughest 2020 candidate on Big Pharma, Donald Trump is calling for new rules on importing drugs from Canada.
Brace yourselves: Two 2020 candidates rolled tough drug-pricing plans in just two days. And rougher waters lie ahead, analysts say.
Change of plans: One day before the Trump administration rule requiring drug list prices in TV ads was to go into effect, a federal judge nixed it.
With drug prices continuing to rise, President Donald Trump wants an executive order to address the problem—but what would it even look like?